AtriCure announced goals for its BoxX-NoAF trial on preventing arrhythmia
On November 17, 2026, AtriCure announced details for its BoxX-NoAF clinical trial, which evaluates cardiac ablation and left atrial appendage exclusion (LAAE) to lower the risk of atrial fibrillation (Afib). The study targets patients with risk factors but no prior history of Afib.
Key points
- The BoxX-NoAF trial examines if combining cardiac ablation and LAAE during cardiac surgery effectively reduces new-onset Afib.
- The study also analyzes whether post-operative Afib can be reduced after cardiac surgery.
Clinical trial goals and methodology
The BoxX-NoAF trial examines if combining cardiac ablation and LAAE during cardiac surgery effectively reduces new-onset Afib. The study targets patients predisposed to the condition who have no prior history of it.
Further research focus
The study also analyzes whether post-operative Afib can be reduced after cardiac surgery. Researchers are collecting data to determine the therapeutic value of preventive procedures in this patient group.
What to watch
Investors should watch for company updates on trial enrollment, a required step for results analysis. Future publication of clinical data in peer-reviewed journals or presentations at medical conferences are expected. No specific timeline for results is currently available.
Original sources
- Twitter-2122781954705682711
- LinkedIn-USA,ASIA,CANADA-urn:li:share:7528547657187938304
- Twitter-2122781967947108803
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow AtriCure
A notification in your browser or on your phone when we publish about AtriCure. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
